Where Can I Buy NAD+ 500mg?
September 9, 2026
Researchers looking for NAD+ 500mg for laboratory research can purchase it from Neuro Peptides. NAD+,
Retatrutide and semaglutide differ mainly in how they interact with hormone receptors in the body. Semaglutide activates one primary target, the GLP-1 receptor. Retatrutide activates three: the GLP-1, GIP, and glucagon receptors. For this reason, semaglutide is called a single GLP-1 receptor agonist, while retatrutide is known as a triple receptor agonist.
This difference is important because these receptors are involved in processes related to appetite, glucose regulation, energy balance, and metabolism in clinical trilals. By targeting three receptors at the same time, retatrutide is being studied as a different approach to metabolic regulation.
Research by Coskun et al. describes retatrutide, also known as LY3437943, as an agonist of the GLP-1, GIP, and glucagon receptors. Semaglutide, in comparison, works through GLP-1 receptor activation.
However, having three receptor targets does not automatically make retatrutide better than semaglutide. Semaglutide is already approved for specific clinical uses, while retatrutide remains investigational. Comparing their mechanisms and available research helps explain how the two compounds differ and what scientists are currently studying.
Semaglutide is a GLP-1 receptor agonist. It is designed to mimic the activity of GLP-1, a naturally occurring hormone released from the gut after eating. GLP-1 plays an important role in regulating blood glucose and appetite.
Semaglutide works by activating GLP-1 receptors. This activity can increase insulin secretion when blood glucose is elevated, reduce glucagon secretion, slow gastric emptying, and influence appetite. Together, these effects can support blood glucose regulation and reduce food intake.
The clinical effects of semaglutide have been studied extensively. In a large randomized trial by Wilding et al., 1,961 adults with overweight or obesity and without diabetes received either once-weekly semaglutide 2.4 mg or placebo alongside lifestyle intervention for 68 weeks.
Participants receiving semaglutide had an average body-weight reduction of 14.9%, compared with 2.4% in the placebo group. The study provides an important clinical reference for understanding the effects associated with GLP-1 receptor activation.
This mechanism also highlights a key difference between semaglutide and retatrutide. Semaglutide primarily targets the GLP-1 receptor, while retatrutide is designed to activate GLP-1, GIP, and glucagon receptors.
Retatrutide is an investigational peptide designed to activate three hormone receptors at the same time: GLP-1, GIP, and glucagon receptors. This is why it is commonly described as a triple receptor agonist.
Each receptor has a different role in metabolic signaling:
Research by Coskun et al. demonstrated activity of retatrutide, also known as LY3437943, at all three receptors. In preclinical mouse studies, the researchers found that its effects on body weight involved both reduced calorie intake and increased energy expenditure.
This three-receptor activity is the main difference between retatrutide and semaglutide. Semaglutide primarily activates the GLP-1 receptor, while retatrutide combines GLP-1, GIP, and glucagon receptor activity in a single molecule. However, retatrutide remains investigational, and findings from animal studies should not be assumed to produce the same effects in humans.
The main difference between retatrutide and semaglutide is the number of hormone receptors they activate. Semaglutide primarily works through the GLP-1 receptor. Retatrutide combines activity at GLP-1, GIP, and glucagon receptors in a single molecule.
This means retatrutide should not simply be viewed as a stronger form of semaglutide. The two compounds use different approaches. Semaglutide relies on GLP-1 receptor signaling, while retatrutide is designed to produce combined effects through three metabolic pathways.
Researchers are studying whether this multi-receptor activity can produce different effects on appetite, glucose regulation, energy expenditure, and body weight. However, targeting more receptors does not automatically mean that a compound is more effective or clinically superior.
| Feature | Retatrutide | Semaglutide |
|---|---|---|
| Type | Triple hormone receptor agonist | GLP-1 receptor agonist |
| Receptors Targeted | GLP-1, GIP, and glucagon | GLP-1 |
| Number of Receptor Targets | Three | One primary target |
| GLP-1 Activity | Yes | Yes |
| GIP Activity | Yes | No |
| Glucagon Activity | Yes | No |
| Metabolic Approach | Multi-receptor signaling | GLP-1 receptor signaling |
| Research Areas | Body weight, glucose regulation, energy expenditure, and metabolic health | Body weight, glucose regulation, appetite, and metabolic health |
| Development Status | Investigational; Phase 3 development | FDA-approved for specific indications |
| Key Difference | Combines three receptor pathways in one molecule | Works primarily through GLP-1 receptor activation |
GIP is one of the incretin hormones responsible for the gut’s role in regulating glucose-dependent insulin secretion and metabolic function. Retatrutide therefore combines two
This multi-receptor concept can also be understood by comparing retatrutide with tirzepatide. Tirzepatide acted on glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, and retatrutide acted on the glucagon receptor in addition to GIP and GLP-1. In the SURMOUNT-1 trial, Jastreboff et al. demonstrated that tirzepatide induced significant weight loss over 72 weeks of follow-up, thus proving the effectiveness of dual GIP/GLP-1 agonism.
Retatrutide therefore represents an expansion of the multi-receptor approach rather than simply another GLP-1 drug.
The addition of glucagon receptor activity is one of the clearest mechanistic differences between retatrutide and semaglutide. Glucagon is involved in energy homeostasis, including hepatic glucose production and energy expenditure. Incretin pathways—GLP-1 and GIP—before adding glucagon receptor activity.
According to Coskun et al., glucagon receptor activation was “associated with increased energy expenditure in rodents,” while “GLP-1 and GIP receptor activation was associated with decreased caloric intake and improved metabolic function.”
Therefore, this information explains the mechanism of action of the triple-agonist. However, mechanistic and animal findings should not be presented as proof of clinical superiority.
Semaglutide has a comparatively mature clinical evidence base. The STEP 1 randomized controlled trial included 1,961 adults with overweight or obesity without diabetes, who received once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks, alongside lifestyle intervention. Participants also experienced improvements in several cardiometabolic risk factors. Nausea and diarrhea were the most common adverse events
These findings provide an established reference point for comparing new metabolic agents.
The drug has shown very promising results in phase II trials in humans. According to Jastreboff et al., in the obesity trial, “patients who received any dose of retatrutide had achieved significantly greater weight reduction from baseline than placebo at week 48; the mean body-weight reduction was 24.2% in the 12-mg group”.
In addition to trials on obesity, the drug was tested on patients with type 2 diabetes. According to Rosenstock et al., “patients with type 2 diabetes who received multiple ascending doses of retatrutide in a phase 2 clinical trial had improvements in glucose levels and body weight”, with the most frequent treatment-emergent adverse events being gastrointestinal events.
Thus, based on the information provided, it is possible to suggest that further preclinical and clinical trials of the drug are necessary, but they do not show that retatrutide is significantly more efficient than semaglutide.
The indicated percentages can demonstrate the extent of change in each of the trials; however, they cannot be used to compare the results directly.
Specifically, semaglutide decreased the patients’ weight by 14.9% on average during 68 weeks in the STEP 1 trial, whereas retatrutide reduced it by 24.2% on average during 48 weeks in the phase 2 obesity trial.
Since those trials were different in many aspects, including the target population, treatment setting, duration, and others, those results cannot demonstrate the superiority of retatrutide over semaglutide.
A Phase 3 study known as TRANSCEND-T2D-2 is specifically designed to compare once-weekly retatrutide with once-weekly semaglutide in adults with type 2 diabetes and inadequate glycemic control despite metformin, with or without an SGLT2 inhibitor. ClinicalTrials.gov lists the study as randomized, multicenter, open-label, and active but not recruiting; its record currently shows no posted results.
This study is particularly important because it addresses a major limitation of cross-trial comparisons: both treatments are being evaluated within the same randomized study framework. Until results are available, however, it would be premature to claim that retatrutide is superior to semaglutide.
It is essential to evaluate the safety of the proposed treatments. In particular, in STEP 1, the incidence of adverse gastrointestinal events, including nausea and diarrhea, was reported as highly prevalent, with treatment discontinuation owing to AE.
The same was noted for retatrutide, as gastrointestinal adverse events were among the most frequently reported ones in the phase 2 obesity trial conducted by Jastreboff et al. Moreover, treatment was associated with increases in heart rate. It should also be noted that the safety of retatrutide is still under investigation, as the drug is experimental and is being examined for a longer period of time.
The main difference between retatrutide and semaglutide is not the fact that one causes significantly higher weight loss than the other, according to the analyzed research.
It is rather the pharmacological characteristic of being a triple agonist of GLP-1, GIP, and glucagon receptors as compared to a GLP-1 receptor agonism only exhibited by semaglutide Coskun et al. Thus, the evidence presented by Wilding et al. and Jastreboff et al. is sufficient to conclude that both medications are associated with substantial weight loss, with retatrutide, according to the researchers, having the potential to elicit greater efficacy versus semaglutide due to its multi-receptor activity, although further direct comparisons are required.
No, retatrutide is not the same drug as semaglutide. It was established that semaglutide is a GLP-1 receptor agonist, whereas retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors, according to Coskun et al.
The phase 2 obesity trial that assessed retatrutide showed more % reduction in weight as compared to the STEP 1 trial for semaglutide. However, the two drugs were tested in different trials. It would be premature to conclude which of the two drugs is more effective based on the results of these trials.
The GLP-1 receptor is one of the three receptors targeted by retatrutide; the other two are the GIP receptor and glucagon receptor.
A phase 3 trial of retatrutide for the treatment of type 2 diabetes is being performed and is directly comparing it to semaglutide; therefore, more data will be necessary before any conclusions can be drawn about the relative efficacy of the two drugs on type 2 diabetes.
No. Retatrutide remains investigational and is still being evaluated in clinical development.
Retatrutide and semaglutide share an important connection with metabolic research but differ substantially in their mechanisms. Semaglutide activates the GLP-1 receptor, whereas retatrutide combines GLP-1, GIP, and glucagon receptor activity.
Clinical research has shown meaningful weight loss with both compounds, but the evidence comes from different trials and cannot establish superiority through indirect comparison. The most informative evidence will come from randomized head-to-head research, including TRANSCEND-T2D-2.
The key difference is therefore not simply how much weight was lost in an individual trial—it is the receptor biology being investigated.
Researchers looking for NAD+ 500mg for laboratory research can purchase it from Neuro Peptides. NAD+,
Mitochondria have long been understood as essential sites of cell energy production; however, accumulating evidence
Researchers looking for Retatrutide 10mg for laboratory research can find this research compound at NeuroPeptides.
MOTS-C is a 16-amino-acid mitochondrial-derived peptide (MDP) that has attracted growing interest in research on
MOTS-C is a mitochondrial-derived peptide (MDP) that has been extensively investigated in the context of
MOTS-C is one of the latest mitochondrial-derived research peptides being investigated with growing interest in